Search
Proline
go.drugbank.com/drugs/DB00172ApprovedInvestigationalNutraceuticalProline is one of the twenty amino acids used in living organisms as the building blocks of proteins.
Mixtures: Nutriflex Lipid special ohne Elektrolyte Emulsion zur Infusion, Nutriflex Omega special ohne Elektrolyte B. Braun Emulsion zur InfusionCinchocaine
go.drugbank.com/drugs/DB00527ApprovedVet approvedIt is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006)
Fruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalTumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon … Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis.
Cefotiam
go.drugbank.com/drugs/DB00229ApprovedOne of the cephalosporins that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
Dexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approvedDexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318] … [L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.
Mixtures: CLOXONA-O, TOBRAMICINA E DESAMETASONE DOC GENERICIProducts: Dexa 0.5% w/v Solution for Injection, MINIMS DEXAMETHASONE SODIUM PHOSPHATE EYE DROPS 0.1% w/vNaxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[A224474] One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). … [L24454] This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies,[A224604] making
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir was approved by the FDA in 1997 to treat a variety of mild to moderate infections and was initially marketed by Abbvie. … [A180739] Because of its chemical structure, it is effective against organisms that are resistant to first-line cephalosporin therapy due to the production of beta-lactamase enzymes.[A180724,A180727]
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalTeduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). … The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012.
Methoxyflurane
go.drugbank.com/drugs/DB01028ApprovedInvestigationalVet approvedWithdrawnIf so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular … (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.[L43942]
Sodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedSodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels [FDA Label]. … Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667]. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.